Eltrombopag for newly diagnosed ITP patients
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with ITP for the first time (not a long-term case).
- Your platelet count must be 30 or lower (a very low level).
- You cannot be pregnant.
- You cannot have ITP caused by another illness (like lupus, hepatitis C, or H. pylori).
- You must not have severe bleeding (grade 3 or 4) or a history of recent infection or vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.